drug · antibody
spesolimab
Marketedupdated 3mo agoby Boehringer Ingelheim International GmbH🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 9 investigational indications.
targets
IL36 receptor
all catalysts(5)
approval · 5
Sep 1, 2022
approval
SPEVIGO (SPESOLIMAB-SBZO) — FDA approval
spesolimab
→
Mar 18, 2024
approval
SPEVIGO (SPESOLIMAB-SBZO) — FDA approval
spesolimab
→
May 28, 2025
approval
SPEVIGO (SPESOLIMAB-SBZO) — FDA approval
spesolimab
→
May 28, 2025
approval
SPEVIGO (SPESOLIMAB-SBZO) — FDA approval
spesolimab
→
Oct 21, 2025
approval
SPEVIGO (SPESOLIMAB-SBZO) — FDA approval
spesolimab
→
Trials studying spesolimab
- phase3A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
- phase3A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
- phase4A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
- phase2Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
- phase2Spesolimab in Pyoderma Gangrenosum
- —Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
- phase3A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
- phase2A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial
News(3)
- Leo Pharma buys rare skin disease drug in $435M dealTanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.biopharma_dive · 2d ago
- LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drugThis is the third recent acquisition conducted by Denmark’s LEO Pharma in medical dermatology, a portfolio that marked 12% growth in the first half of the year.biospace · 2d ago
- Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nodLeo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval decision by the…fiercebiotech · 3d ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that